Addex Therapeutics
ADXN
2 hedge funds and large institutions have $274 invested in Addex Therapeutics in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 3 closing their positions.
0.03% less ownership
Funds ownership: 0.04% → 0% (-0.03%)
50% less funds holding
Funds holding: 4 → 2 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
89% less capital inflows, than outflows
Capital inflows: $309 | Capital outflows: $2.85K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$309 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.89K |
| 2 |
GAMMA Investing
Foster City,
California
|
-$509 |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$450 |
ADXN Hedge Fund Activity: Q2 2026 in Review
2 of the 8,377 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q2 2026, worth a combined $274 — down 90% from $2.86K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ADXN and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $309. The largest seller was Morgan Stanley, exiting entirely with an estimated $1.89K sold.
- 2 institutional investors held Addex Therapeutics (ADXN) as of Q2 2026, down from 4 in Q1 2026.
- Funds reported $274 of Addex Therapeutics stock for Q2 2026, down 90% quarter-over-quarter.
- 1 fund opened new Addex Therapeutics positions in Q2 2026 and 3 closed out, a net change of -2 holders.
- The largest Addex Therapeutics buyer in Q2 2026 was UBS Group, an estimated $309 added.
- The largest Addex Therapeutics seller in Q2 2026 was Morgan Stanley, an estimated $1.89K sold.
Based on aggregated 13F filings for Q2 2026.